213118-56-0

Basic information

• Product Name: (2-AMINO-4-METHOXY-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (2-AMINO-4-METHOXY-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER
• CAS NO: 213118-56-0
• Molecular Formula: C₁₂H₁₈N₂O₃
• Molecular Weight: 238.28
• Mol File: 213118-56-0.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (2-AMINO-4-METHOXY-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2-AMINO-4-METHOXY-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(213118-56-0)
• EPA Substance Registry System: (2-AMINO-4-METHOXY-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(213118-56-0)

Safety Data

• Hazardous Substances Data: 213118-56-0(Hazardous Substances Data)

Usage

General Description

(2-AMINO-4-METHOXY-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is a chemical with the molecular formula C12H18N2O4. It is a tert-butyl ester derivative of (2-amino-4-methoxyphenyl)carbamic acid, and is commonly used in the field of organic synthesis. (2-AMINO-4-METHOXY-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER has potential pharmaceutical applications and can be used as a building block in the synthesis of various pharmaceutical compounds. It is important to handle this chemical with caution and adhere to proper safety protocols due to its potential health hazards.

Upstream product

• 185428-90-4 (4-methoxy-2-nitro-phenyl)-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 96-96-8 4-methoxy-2-nitroaniline 
• 33844-21-2 2-nitro-4-methoxybenzoic acid 
• 50424-96-9 4-methoxy-2-nitro-benzoyl chloride 
• 1026319-38-9 4-Methoxy-2-nitro-benzoyl azide 
• 1218786-41-4 N-Boc-2-(2',2',2'-trichloroacetylamino)-4-methoxyaniline 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 610-81-1 4-hydroxy-2-nitroaniline 

Downstream Products

• 1027928-51-3 (2-Benzylamino-4-methoxy-phenyl)-carbamic acid tert-butyl ester 
• 213118-57-1 1-(N-methyl)-2-(N-tert-butoxycarbonyl)-4-methoxy-1,2-phenylenediamine 
• 213118-59-3 1-(2-Amino-5-methoxy-phenyl)-1,3-dimethyl-urea 
• 213118-58-2 [2-(1,3-Dimethyl-ureido)-4-methoxy-phenyl]-carbamic acid tert-butyl ester 
• 942220-44-2 1-Benzyl-6-methoxy-1,3-dihydro-benzoimidazol-2-one 
• 1026308-74-6 1-Benzyl-2-chloro-6-methoxy-1H-benzoimidazole 
• 184832-24-4 1-Benzyl-6-methoxy-2-piperazin-1-yl-1H-benzoimidazole 
• 579477-16-0 {4-methoxy-2-[3-oxo-3-(3-pyridin-4-yl-phenyl)-propionylamino]-phenyl}-carbamic acid tert-butyl ester 
• 1034495-87-8 N-(2-t-butoxycarbonylamino-5-methoxyphenyl)-4-[1-(2-dimethylaminoethyl)-3-(indan-5-yl)ureidomethyl]benzamide 
• 1297603-81-6 C₃₃H₄₄ClN₃O₅ 
• 2080-75-3 5-methoxy-1,3-dihydro-2H-benzoimidazol-2-one 
• 1354030-44-6 5-(3-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)propoxy)-1H-benzo[d]imidazol-2(3H)-one 
• 1354030-54-8 5-(4-(4-(2,3-dichlorophenyl)piperidin-1-yl)butoxy)-1H-benzo[d]imidazol-2(3H)-one 
• 1354030-70-8 5-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)-1H-benzo[d]imidazol-2(3H)-one 

Relevant articles and documents

Cyclometalated iridium(III) bipyridyl-phenylenediamine complexes with multicolor phosphorescence: Synthesis, electrochemistry, photophysics, and intracellular nitric oxide sensing

We present a new class of phosphorescent cyclometalated iridium(III) bipyridyl-phenylenediamine complexes [Ir(N^C)2(bpy-DA)](PF 6) (bpy-DA=4-(N-(2-amino-5-methoxyphenyl)aminomethyl)-4′- methyl-2,2′-bipyridine; HN^C=2-(2,4-difluorophenyl)pyridine (Hdfppy) (1-a), 2-phenylpyridine (Hppy) (2-a), 2-phenylquinoline (Hpq) (3-a), 2-phenylcinchoninic acid methyl ester (Hpqe) (4-a)) and their triazole counterparts [Ir(N^C)2(bpy-T)](PF6) (bpy-T=4-((6- methoxybenzotriazol-1-yl)methyl)-4′-methyl-2,2′-bipyridine; HN^C=Hdfppy (1-b), Hppy (2-b), Hpq (3-b), Hpqe (4-b)). Upon photoexcitation, the diamine complexes exhibited fairly weak green to red phosphorescence under ambient conditions whereas the triazole derivatives emitted strongly. The photophysical properties of complexes 2-a and 2-b have been studied in more detail. Upon protonation, the diamine complex 2-a displayed increased emission intensity, but the emission properties of its triazole counterpart complex 2-b were independent on the pH value of the solution. Also, complex 2-a was found to be readily converted into complex 2-b upon reaction with NO under aerated conditions, resulting in substantial emission enhancement of the solution. The reaction was highly specific toward NO over other reactive oxygen and nitrogen species (RONS) as revealed by spectroscopic analyses. The lipophilicity and cellular uptake efficiency of the diamine complexes have been examined and correlated to their molecular structures. Also, cell-based assays showed that these complexes were noncytotoxic toward human cervix epithelioid carcinoma (HeLa) cells (at 10 μM, 4 h, percentage survival ≈80-95-%). Additionally, the diamine complexes have been used to visualize intracellular NO generated both exogenously in HeLa cells and endogenously in RAW 264.7 murine macrophages by laser-scanning confocal microscopy. Visualizing NO: Phosphorescent cyclometalated iridium(III) bipyridyl-phenylenediamine complexes have been designed as intracellular NO sensors. They react selectively with NO over other reactive oxygen and nitrogen species and are converted into their triazole counterparts, resulting in significant emission enhancement. The diamine complexes show low cytotoxic activity and are capable of sensing intracellular NO generated exogenously in HeLa cells and endogenously in RAW 264.7 murine macrophages.

FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS

The present invention relates to novel functionally selective ligands of dopamine D2 receptors, including agonists, antagonists, and inverse agonists. The invention further relates to the use of these compounds for treating central nervous system disorders related to D2 receptors.

NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE

The present invention relates to a study on the sy nthesis of a novel N-(2-aminophenyl)benzamide derivativ e having an urea structure and represented by the genera l formula (1); and the utilization of a pharmacological effect of the derivative. A compoun